Hospital acquired  infection in pediatric wards: a retrospective case–control study by unknown
Karaaslan et al. SpringerPlus  (2016) 5:1329 
DOI 10.1186/s40064-016-3013-8
RESEARCH
Hospital acquired Clostridium difficile 
infection in pediatric wards: a retrospective 
case–control study
Ayse Karaaslan1, Ahmet Soysal1*, Nurhayat Yakut1, Gulsen Akkoç1, Sevliya Ocal Demir1, Serkan Atıcı1, 
Nurver Ulger Toprak2, Guner Söyletir2 and Mustafa Bakır1
Abstract 
Background: Clostridium difficile is a major cause of antibiotic-associated diarrhea and frequently results in health-
care-associated infections. The aim of this study was to determine the incidence and potential risk factors for C. difficile 
infection (CDI) in hospitalized children who developed diarrhea. A retrospective study was performed at a university 
hospital in İstanbul over a three-year period (2012–2014).
Results: During the study period 12,196 children were hospitalized, among them 986 (8 %) children with diarrhea 
were investigated for CDI and 100 (0.8 %) children were diagnosed with CDI. The incidence of CDI in hospitalized chil-
dren was 4/1000, 9/1000 and 9/1000 patients per year in year 2012, 2013 and 2014, respectively (p = 0.008, p < 0.01). 
The mean age of children with CDI (2.6 ± 2.6 months) was lower than children without CDI (57.5 ± 63.5 months) 
[p = 0.001]. In the multivariate analysis, the presence of underlying chronic diseases [presence of malnutrition (OR 7, 
95 % CI 1.33–36.7, p = 0.021), presence of solid organ tumors (OR 6, 95 % CI 2.4–15.7, p < 0.00), presence of congenital 
heart diseases (OR 4.6, 95 % CI 1.13–18.7, p = 0.03), hospitalization in PICU (OR 15.6, 95 % CI 3.2–75.8, p = 0.001) and 
hospitalization in hematology and oncology ward (OR 7.8, 95 % CI 2–29.9, p = 0.002)] were found to be independent 
risk factors for CDI.
Conclusion: This is the first description of the incidence and associated risk factors of CDI in Turkish children. One of 
the most important risk factor was prior antibiotic exposure which emphasizes the importance of antibiotic steward-
ship programs.
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Background
Clostridium difficile is an anaerobic Gram positive, toxin-
producing and spore forming bacillus that can cause a 
range of illnesses from antibiotic-associated mild diar-
rhea to fulminant diseases such as pseudomembranous 
colitis, sepsis and death (Nylund et al. 2011). C. difficile 
spores are resistant to heat, disinfectants and antibiot-
ics and they can survive in hospital environment for 
several months. Contaminated medical devices lead to 
transmission to patients, especially by health care work-
er’s hands (Kim et al. 1981).
Clostridium difficile is one of the most common 
healthcare-associated infections and it is responsible for 
15–25  % of cases of nosocomial antibiotic-associated 
diarrhea (Lessa et al. 2015; Bartlett 2002). C. difficile can 
be detected in stool specimens without symptoms in 
up to 70 % of children during the first year of life (Bry-
ant and McDonald 2009). Colonization rates decrease as 
age increases and after almost 4 years of age becomes less 
than 5 % (Vernacchio et al. 2006). It causes diarrhea due 
to alteration of colonic flora, which is generally caused 
by antibiotic therapy and ingestion of the microorganism 
leading to toxin production followed by mucosal injury 
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and inflammation (Nylund et al. 2011). C. difficile infec-
tion (CDI) is related to A and B toxins, which are the 
major virulence factors of C. difficile. They both cause 
mucosal damage; however, Toxin B is about ten times 
more virulent than Toxin A. CDI severity is associated 
with the fecal toxin levels (Lyras et al. 2009; Warny et al. 
2005). There is also a hypervirulent strain of C. difficile 
(NAP1/BI/027) which is associated with more violent 
disease (Petrella et al. 2012).
CDI is more common in adults than children; however, 
recent studies reported that CDI hospitalization rates are 
increasing in children, especially as a result of increased 
use of antibiotics and changes in the demographics of 
hospitalized patients. 1–5-year old children have the 
highest incidence of CDI (Deshpande et  al. 2013; Zil-
berberg et  al. 2010; Khanna and Pardi 2012). The most 
important and well-known risk factor for CDI is antibi-
otic exposure, with penicillins, clindamycin, cephalo-
sporins, and fluoroquinolones implicated in the majority 
of cases (Nylund et  al. 2011; Leffler and Lamont 2015). 
Children exposed to proton pump inhibitors, acid sup-
pression medication, and those who have a gastrostomy 
or jejunostomy tube are also at risk of CDI (Freedberg 
et al. 2015; Turco et al. 2010; Sandora et al. 2011).
This study was performed to report the incidence of C. 
difficile and its risk factors in hospitalized children in our 
hospital, as no previous data exists in our country.
Methods
The study was performed in a tertiary university hospi-
tal with a 649-bed capacity including all major pediatric 
wards and neonatal and pediatric intensive care units. 
We retrospectively reviewed the medical records and 
ICD codes of pediatric patients aged between 0 months 
and 18 years who had the diagnosis of diarrhea and ICD 
(International Classification of Diseases) code for C. diffi-
cile between January 2012 and December 2014. Patients’ 
age and gender distribution, pediatric ward type, num-
ber of patients with underlying diseases, implicated anti-
biotics, and length of antibiotic usage were noted. The 
study protocol was approved by the Ethics Committee 
of Marmara University Medical School. Informed writ-
ten consent was obtained from all participants’ parents/
guardians on admission for all diagnostic tests and treat-
ment protocol.
Patient group consisted of all children who devel-
oped diarrhea 48  h after hospitalization in whom CDI 
was diagnosed. Children with community aquired diar-
rhea were excluded from the study. A case–control 
study was conducted, comparing CDI patients with 
non-CDI patients who had diarrhea. The control group 
consisted of children who developed diarrhea 48 h after 
hospitalization in whom CDI was investigated, but toxin 
A and/or toxin B were negative for C. difficile in stool 
specimens.
CDI was defined as the presence of the following two 
findings: (1) diarrhea defined as three or more unformed 
stools within 24  h, (2) a positive cytotoxic stool assay 
for the presence of toxin A and/or toxin B (Cohen et al. 
2010). Qualitative detection of toxins A and B of C. diffi-
cile was performed using Premier toxins A and B (C. dif-
ficile) EIA kit bioMérieux, (Marseille, France) according 
to the manufacturer’s instructions.
All patients with the diagnosis of health care associ-
ated CDI that had clinical symptoms such as fever and/or 
increase of white blood cell count received antimicrobial 
therapy. Metronidazole (30 mg/kg per day divided into 3 
or 4 doses) was administered for a minimum of 10 days.
For statistical analysis, the Number Cruncher Statisti-
cal System (NCSS) 2007 (Kaysville, Utah, USA) statistical 
software programs was used. For univariate analysis, stu-
dent’s test, Pearson χ2, and Fisher-Freeman-Halton exact 
tests were used for categorical and continuous variables. 
Categorical variables were further tested if appropriate in 
a multivariate analysis by using logistic regression analy-
sis. Significance was set at p < 0.05.
Results
Between January 2012 and December 2014, 12196 chil-
dren were hospitalized in our hospital. Among them 
986 (8  %) children who developed diarrhea 48  h after 
hospitalization were investigated for CDI. In total, 100 
(0.8  %) children developed CDI. The incidence of CDI 
in hospitalized children was 4/1000, 9/1000, and 9/1000 
patient per year in years 2012, 2013, and 2014, respec-
tively (p = 0.008; p < 0.01). The mean age of children with 
CDI was 2.6 ±  2.6  months. The median time for hospi-
talization in CDI patients was 12 days (range 1–180, mean 
24.2 ± 32.8). Among the 100 patients diagnosed with CDI, 
69 (69  %) received antibiotic therapy prior to develop-
ment of diarrhea; and among control patients 522 (58.9 %) 
received antibiotic therapy. The most common antibiot-
ics used among total patients were meropenem (n = 158, 
16 %), piperacillin–tazobactam (n = 122, 12.4 %), vanco-
mycin (n = 121, 12.3 %), ceftriaxone (n = 95, 9.6 %), teico-
planin (n = 65, 6.6 %), cefepime (n = 61, 6.2 %), liposomal 
amphotericin b (n = 54, 5.5 %), ampicillin (n = 51, 5.2 %) 
and ampicillin-sulbactam (n = 50, 5.1 %).
Univariate analysis found that patients’ age, pres-
ence of underlying chronic diseases, hospitalization in 
pediatric intensive care unit (PICU), hospitalization in 
hematology/oncology ward, and antibiotic usage prior to 
development of diarrhea were risk factors (Table  1) for 
developing CDI.
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The multivariate analysis found that the presence of 
underlying chronic diseases [presence of malnutrition 
(OR 7, 95 % CI 1.33–36.7, p = 0.021), presence of solid 
organ tumors (OR 6, 95  % CI 2.4–15.7, p  <  0.00), pres-
ence of congenital heart diseases (OR 4.6, 95 % CI 1.13–
18.7, p = 0.03), hospitalization in PICU (OR 15.6, 95 % CI 
3.2–75.8, p  =  0.001) and hospitalization in hematology 
and oncology ward (OR 7.8, 95 % CI 2–29.9, p = 0.002)] 
were independent risk factors (Table  2). Older age (OR 
0.72, 95 % CI 0.6–0.79, p < 0.001) was found to be protec-
tive for CDI.
The total hospital costs included all costs associ-
ated with hospitalization. Although the total hospi-
talization cost of patients with CDI (total cost was 
$4578) were higher than those without CDI (total cost 
was $3528), this difference was not statistically sig-
nificant (p  =  0.169). Mean length of hospitalization 
in the CDI group was 24.2  ±  32.8  days, compared to 
21.3 ± 24.9 days in the non-CDI patients with diarrhea. 
The length of hospitalization in CDI group was longer; 
however, the difference was not significant (p = 0.304). 
In our study, there were no children unresponsive to 
treatment and all 100 patients showed clinical remis-
sion with the clearence of the symptoms. No CDI related 
mortality was observed.
Discussion
Our study found the incidence of CDI in hospitalized 
children to be 4/1000, 9/1000, and 9/1000 per year in 
2012, 2013, and 2014, respectively and this is the first 
report of CDI incidence in children in Turkey. We are 
therefore unable to compare our study with any other 
study in Turkey. Zilberberg et  al. (2010) reported that 
pediatric CDI hospitalization rates increased from 7.2 
to 12.8 from 1997 through 2006. The anticipated inci-
dence of CDI for children under 18 years of age was 24.2 
cases per 100,000 population according to active surveil-
lance in the United States in 2011 and suprisingly about 
two-thirds of the cases were community associated CID 
(Lessa et al. 2015). Many children with community asso-
ciated CDI lack the classicial risk factor of antibiotic 
exposure (Tschudin-Sutter et al. 2013). One of the newer 
studies from United States showed that CDI incidence 
in hospitalized children increased from 24.0 to 58.0 per 
10,000 discharges per year (Pant et  al. 2016). We also 
found increasing incidence in our study, similar to the 
literature.
Newborns rarely develop symptomatic C. difficile 
infection because of the protective effect of mater-
nal antibodies, premature immune system and maybe 
the lack of intestinal receptors for C. difficile tox-
ins (Nylund et  al. 2011; McFarland et  al. 2000). In 
our study median age of the patients with CDI was 
2.6 ±  2.5 months. In infant population, three or more 
stools per day can be accepted as normal physiology. 
For this reason, diarrhea was accepted as at least three 
or more watery stools that exceeds the child’s usual 
number of daily stools, and the diagnosis of CDI was 
made by a neonatologist in all newborns. Coloniza-
tion with C. difficile is common in infants; however, we 
did not screen for asymptomatic colonization, we only 
investigated toxins A and B of C. difficile in stool sam-
ples in children with diarrhea, fever, and/or increase of 
white blood cell count. Our hospital is a tertiary uni-
versity hospital and critically ill patients are usually 
transferred to our hospital, explaining the reason for a 
low average age. Although we tried to diagnose CDI, we 
Table 1 Univariate analysis of  risk factors for  C. difficile 
infection among hospitalized patients
C. difficile: Clostridium difficile, CDI C. difficile infection, PICU pediatric intensive 
care unit
Variable CDI n, (%) Non-CDI n, (%) p value
Mean age (month) 2.62 ± 2.59 57.4 ± 63.57 0.001
Gender
 Female 37 (8.5) 397 (91.5) 0.136
 Male 63 (11.4) 489 (88.6)
Presence of underlying chronic 
diseases
83 (83) 636 (71.7) 0.004
Hematology/oncology stay 41 (11.8) 305 (88.2) 0.005
PICU stay 13 (17.1) 63 (82.9) 0.001
Antibiotic usage prior to CDI 69 (11.7) 522 (88.3) 0.051
Table 2 Multivariate analysis of risk factors for C. difficile infection among hospitalized patients
C. difficile: Clostridium difficile, CDI C. difficile infection, PICU pediatric intensive care unit
Variable CDI n, (%) Non-CDI n, (%) OR 95 % CI p value
Presence of underlying chronic diseases 83 (11.5) 636 (88.5) – – 0.005
Malnutrition 5 (20) 20 (80) 7 1.3–36.7 0.021
Solid organ tumor 23 (15.8) 123 (84.2) 6.1 2.4–15.7 0.001
Congenital heart disease 7 (23.3) 23 (76.7) 4.5 1.1–18.6 0.033
Hematology/oncology stay 41 (11.8) 305 (88.2) 7.8 2–29.9 0.002
PICU stay 13 (17.1) 63 (82.9) 15.6 3.2–75.8 0.001
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think we could not definetly distinguish infection from 
colonization because of the younger age of the study 
group. All patients were reported to the infection con-
trol committee and isolated in a private room. In addi-
tion to standard precautions, contact precautions were 
also taken for the duration of the illness.
Many studies have investigated the risk factors for CDI 
in hospitalized patients. Previous studies have reported 
that antibiotic exposure is the leading risk factor asso-
ciated with CDI and proton pump inhibitors, acid sup-
pression medication, gastrostomy or jejunostomy tubes, 
and malignancy have also been found as risk factors 
(Leffler and Lamont 2015; Freedberg et  al. 2015; Turco 
et al. 2010; Sandora et al. 2011; Cohen et al. 2010; Sam-
ady et al. 2014). In our study, we found the presence of 
underlying chronic diseases such as malnutrition, con-
genital hearth diseases, malignancy, and stay in PICU 
as risk factors for CDI. We believe that malnutrition, 
admission to PICU, and malignancy may cause second-
ary immunocompromisation that facilitates CDI. How-
ever, congenital hearth disease was a suprising find as a 
risk factor for CDI, which was not previously defined. 
Although the total hospitalization costs of patients with 
CDI was higher than those without CDI, the difference 
was not statistically significant.
The treatment of CDI is based on discontinuation of 
inciting antibiotics, supportive care, and antimicribial 
therapy. Metronidazole is recommended for the therapy 
of mild or moderate CDI; however, vancomycin is pre-
ferred in severe or complicated diseases in children and 
adolescents for 10–14  days (Schutze and Willoughby 
2013). In our study, we preferred metronidazole as the 
first agent, used for a minimum 10 days.
In our practical approach, we also investigate the hos-
pitalized patients with diarrhea for rotavirus, adenovi-
rus, giardia antigen, entamoeba antigen and bacterial 
stool culture which are possible to be diagnosed in our 
microbiological department. However because of our 
retrospective study design, in this study, we have only 
recorded the data of patients with the diagnosis of CDI 
whom were negative for other investigated pathogens.
This study has several limitations. Firstly, we did not 
collect all the ethiological agents of children with diar-
rhea without CDI. Secondly, we compared the risk fac-
tors in patients with diarrhea with CDI and children with 
diarrhea due to non-CDI; we did not compare patients 
with CDI between themselves. We compared the total 
hospital cost of patients with CDI and patients with diar-
rhea without CDI and the difference was not significant. 
However, if we had compared the patients with CDI 
and patients without diarrhea, we believe the difference 
would be significant, similar to previous reports in litera-
ture (McGlone et al. 2012).
Conclusion
In this study, CDI was responsible for 10 % of cases of 
nosocomial-associated diarrhea. Prior antibiotic expo-
sure was found to be a risk factor, emphasizing the 
importance of antibiotic stewardship programs. Addi-
tionally, PICU stay and hematology/oncology ward stay 
were the independent risk factors for CDI. These fac-
tors are uncontrollable and therefore infection control 
programs are the most important measures to prevent 
CDI.
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